RESUMEN
BACKGROUND: Glycoprotein IIb IIIa inhibitors improved short- and long-term outcome when added to primary percutaneous coronary intervention (PPCI) in patients with ST-segment-elevation myocardial infarction (STEMI). We hypothesized that intracoronary eptifibatide infusion via a perfusion catheter improves angiographic and clinical outcome of patients with STEMI undergoing PPCI, versus conventional intracoronary bolus injection. METHODS: Prospectively, we enrolled 80 patients with acute STEMI and thrombolysis in myocardial infarction (TIMI) thrombus grade ≥ 2. Patients were assigned to receive eptifibatide (180 µg) either via a dedicated coronary perfusion catheter (ClearWayTM) during PPCI (group I), or guiding catheter (group II). Assessment of TIMI thrombus grade, TIMI flow grade, and TIMI myocardial perfusion (TMP) grade was performed both at baseline and post- procedurally. The primary 'angiographic' endpoint was final TMP grade 0/1. The primary 'clinical' endpoint was a composite of cardiac death, non-fatal re-infarction, target vessel revascularization, and recurrent ischemia at 30-day follow-up. RESULTS: Mean age was 52.3 ± 8.9 years (17.5% females). Clearance of visible thrombus (TIMI thrombus grade 0) at final angiogram was more frequent in group I. Additionally, both final TIMI flow grade 3 and final TMP grade 3 occurred more frequently in group I. The primary angiographic endpoint was more frequent in group II versus group I (17.5% versus 0%, respectively, p = 0.001). The primary clinical endpoint was more frequent in group II (20% versus 0%, respectively, p = 0.003). CONCLUSIONS: In patients with STEMI, intracoronary eptifibatide infusion via a perfusion catheter during PPCI improved immediate angiographic outcome, and reduced clinical events at 30-day follow-up, versus bolus injection via the guiding catheter.
RESUMEN
BACKGROUND: Cardiac resynchronization therapy (CRT) has a morbidity and mortality benefits in moderate to severe heart failure. It reduces mortality and hospitalization and improves cardiac function. It can be used according to the European guidelines in severely depressed left ventricular ejection fraction (i.e., ≤35%) and complete left bundle branch block. However, 30% of patients may show no benefit from CRT therapy. Therefore, prediction of CRT response seems to be an important subject for study in the current researches. We aimed to study the correlation between Surface ECG QRS complex duration (QRS) duration and cardiac output measured by ventricular outflow tract velocity time integral (LVOT VTI) as a predictor of response in patients with CRT implantation. METHODS: We studied 100 consecutive patients prospectively with biventricular pacing system. The patients were studied at the pacemaker follow-up clinic. Each patient was subjected to: Full medical history, general and local examination, a 12 lead electrocardiogram and QRS duration in ms was measured. All patients were subjected to a focused transthoracic echocardiographic examination in which a parasternal long axis view was obtained to measure the diameter of the LVOT diameter in mid-systole. The LVOT VTI was measured by pulsed-wave Doppler in the LVOT using a 2-mm sample volume positioned just proximal to the aortic valve in the apical five chamber view. RESULTS: We found a statistically significant difference between CRT responders and nonresponders as regards age, body surface area (BSA), time since CRT implantation and smoking status (P = 0.018, 0.039, 0.002, <0.001). There was negative significant correlation between QRS duration and LVOT VTI and stroke volume index. The optimal cut off values for optimal response to CRT using receiver operating characteristics curves were 130 ms for postimplant QRS duration and 17.1 cm for LVOT VTI. We also found a significant difference between responders and nonresponders as regard CO. It was higher in responders (5.97 vs. 3.34, P < 0.001). CONCLUSION: CRT response is more in patients with lower BSA, and without previous history of ischemic heart disease or smoking. There is a significant negative correlation between QRS duration and LVOT VTI.
RESUMEN
BACKGROUND: Pulmonary vein electrical isolation (PVI) is an effective treatment for atrial fibrillation (AF). However, recurrence of pulmonary vein (PV) conduction after ablation may limit long-term success. Early identification and treatment of acute PV conduction recovery during initial ablation may have an impact on subsequent clinical results. OBJECTIVE: To assess the prevalence of acute PV conduction recovery during the observation time after PV isolation for paroxysmal AF, and to evaluate the impact of re-isolation treatment on long-term clinical results. METHODS: 76 patients with paroxysmal AF were randomized to 2 groups to undergo PVI. Group A (Study Group: 38 patients): 30 minutes of observation were given following PV isolation for detection of acute PV-reconnection, with re-ablation of reconnected PVs. Group B (Control Group: 38 patients). Ablation procedure was done either by conventional method or using 3D electro-anatomical mapping. Symptoms, ECG and Holter monitoring were used to evaluate the clinical effectiveness of ablation. Any episode of symptomatic or asymptomatic atrial tachyarrhythmia that lasted more than 30 seconds documented with ECG or Holter monitoring was considered a recurrence. RESULTS: There was no statistically significant difference in age, sex, AF history, previous AF ablation, structural heart diseases & antiarrhythmic drug history among both groups. In the study group, 14 patients (36.8%) showed no PV reconnection, while 24 patients (63.2%) showed acute PV reconnection within 30 minutes. The LSPV showed the highest rate of acute PV reconnection during the observation period (66.6% of patients showing PV reconnection). AF recurred in only 6 patients (15.8%) in the study group in comparison to 20 patients (52.6%) having AF recurrence post-ablation in the control group. Among 24 patients of the study group, who showed PV reconnection which was re-isolated, only 4 patients (16.7%) had AF recurrence on follow up. In patients who did not show PV reconnection (14 patients), only 2 patients (14.3%) had AF recurrence on follow up. CONCLUSION: Re-isolation of recovered PV conduction contributed to the improvement in the success rate of ablation for paroxysmal AF.
RESUMEN
BACKGROUND: Maximal hyperemia is the critical prerequisite for fractional flow reserve (FFR) assessment. Despite intravenous (IV) adenosine currently being the recommended approach, intracoronary (IC) administration of adenosine constitutes a valuable alternative in everyday practice. However, it is surprisingly unclear which IC strategy allows the achievement of FFR values that are comparable to IV adenosine. OBJECTIVES: This study sought to compare increasing doses of IC adenosine versus IV adenosine for FFR. METHODS: 30 intermediate coronary stenoses undergoing FFR measurement were prospectively and consecutively enrolled. Hyperemia was sequentially induced by bolus of IC adenosine (ADN; 150 µg) followed by IV adenosine (IVADN) infusion over 3 minutes at dose of (140 µg/kg/min). FFR values, symptoms, and development of atrioventricular block were recorded. RESULTS: 150 µg doses of IC adenosine were well tolerated and associated with fewer symptoms than IV adenosine. Intracoronary adenosine doses induced a significant decrease of FFR compared with baseline levels (P < 0.01). Among the 6 patients with FFR values less than 0.80 identified by IVADN, 4 were correctly identified also by 150 µg bolus IC adenosine. Larger randomized studies with cross-over design are necessary to verify the results. CONCLUSIONS: This small pilot study suggests that IC adenosine might be an alternative to IV adenosine. Larger randomized studies with a cross-over design are necessary.